To study serum levels of suPAR in patients with chronic pruritus of unknown origin (CPUO) compared to chronic atopic dermatitis (cAD) and to explore associations between suPAR levels and clinical course, particularly pruritus intensity.
Key Findings:
CPUO patients had the highest suPAR levels (3.2 ± 2.5 ng/ml) compared to controls (2.9 ± 1.1 ng/ml) and cAD patients (2.0 ± 0.9 ng/ml, p = 0.018).
Higher baseline suPAR levels in CPUO participants correlated with increased pruritus intensity at follow-up (p < 0.05).
Interpretation:
The study suggests that systemic chronic inflammation is relevant in CPUO, with suPAR potentially serving as a significant biomarker for its longitudinal course and clinical management.
Limitations:
The study's sample size may limit the generalizability of the findings, particularly in diverse populations.
The observational nature of the study does not establish causation, which should be considered when interpreting results.
Conclusion:
suPAR may be a useful biomarker associated with chronic pruritus of unknown origin, warranting further investigation in clinical practice.
by Stefan M. Kahnert, Lara Jürgens, Leonie Dreher, Christian Schmidt-Lauber, Ansgar Koechel, Gina L. Frank, Tobias B. Huber, Meike Shedden-Mora, Sonja Ständer, Markus Ramm, Gudrun Schneider, Rupert Conrad
Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.
